Protalix BioTherapeutics (PLX) Non-Current Debt (2011 - 2017)

Protalix BioTherapeutics has reported Non-Current Debt for 6 years, with the latest figure at $4.3 million in Q3 2017.

• On a quarterly basis, Non-Current Debt changed 0.0% year-over-year to $4.3 million in Q3 2017; TTM through Sep 2017 was $4.3 million, a 0.0% change from a year earlier, with the FY2016 full-year figure at $4.3 million, changed 0.0% from the prior year.
• Non-Current Debt was $4.3 million for Q3 2017 at Protalix BioTherapeutics, roughly flat from $4.3 million in the prior quarter.
• The five-year high for Non-Current Debt was $4.3 million in Q4 2015, with the low at $376000.0 in Q2 2013.
• Average Non-Current Debt over 4 years is $3.6 million, with a median of $4.3 million recorded in 2015.
• The sharpest annual moves came in 2013 and 2016: Non-Current Debt sank 91.97% in 2013, then changed 0.0% in 2016.
• Over 4 years, Non-Current Debt stood at $2.4 million in 2013, then jumped by 81.4% to $4.3 million in 2015, then changed by 0.0% to $4.3 million in 2016, then changed by 0.0% to $4.3 million in 2017.
• The last three Non-Current Debt figures came in at $4.3 million (Q3 2017), $4.3 million (Q2 2017), and $4.3 million (Q1 2017), per Business Quant data.